Shanghai Pharmaceuticals: The approval number for the fusafungine nasal spray has been obtained from the US FDA.

Zhifu Capital News APP News, Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary Zhejiang Xinyi Ruijue Pharmaceutical Co., Ltd. (hereinafter referred to as "Xinyi Ruijue") recently received a notification from the US Food and Drug Administration (FDA) that its Abbreviated New Drug Application (ANDA) for Mometasone Furoate Nasal Spray (details can be found in the text, hereinafter referred to as "the drug") has been approved.